| SUNDAY |
| 2:00 pm - 9:00 pm | Arrival and Check-in (Office Closed 6:00 pm - 7:00 pm) |
| 6:00 pm | Dinner |
| 7:30 pm - 7:45 pm | Welcome / Introductory Comments by GRC Site Staff and Chairs |
| 7:45 pm - 9:30 pm | Metals in Disease - New Frontiers in Iron Homeostasis |
| The Metals in Medicine GRC covers a broad range of topics that have evolved to provide an alternative to the traditional carbon-based approach to drugs. The successes include Pt-based drugs as well as agents that are used as MRI imaging and radiopharmaceutical agents. Metals ions as vitamins are essential nutrients. They serve as key components in proteins, and countless places in metabolism. Indeed, iron homeostasis central to human well being, is maintained by many newly identified genes and impacts diseases afflicting millions of Americans with, e.g. hemochromatosis, Sickle Cell disease, Thalassemia, iron deficiency anemia and several disease of the central nervous system; iron levels are closely monitored by physicians. A recent example of the US FDA approval of the ultrasmall iron oxide nanoparticle ferumoxytol to treat iron deficiency in patients with chronic kidney disease. In this introductory session of the Metals in Medicine conference three presentations on processes associated with iron metabolism will be presented. First, current and future targets will be overviewed and presented. Second, a mechanistic presentation will illustrate the strategy of mechanistic studies paving the way for developments of devising a strategy for a cure. Finally, the third presentation involves the use of phenomenological data in nutrition to connect metal availability and disease state highlighting the many infections that eventually occur in this compromised human patient population. |
| Discussion Leaders: Debbie C. Crans (Colorado State) and Jan Reedijk (Leiden University) |
| 7:45 pm - 8:15 pm | Elizabeth Theil (CHORI, UC Berkeley)
"Iron in disease, a target for 21st century therapeutics" |
| 8:15 pm - 8:25 pm | Discussion |
| 8:25 pm - 8:50 pm | Andrew J. Ghio (Clinical Research, EPA, North Carolina)
"Iron and oxidative stress in normal and diseased tissue" |
| 8:50 pm - 9:00 pm | Discussion |
| 9:00 pm - 9:25 pm | Alvin Crumbliss (Duke University)
"Hijacking Fe: The mechanism of Fe transport from outside the outer membrane, across the periplasm, to the cytosol in a pathogenic bacterium" |
| 9:25 pm - 9:30 pm | Discussion |
| 9:45 pm - | Chair's Reception |
| MONDAY |
| 7:30 am - 8:30 am | Breakfast |
| 8:30 am | Group Photo |
| 9:00 am - 12:30 pm | Platinum Anticancer Agents |
| Clinical and pre-clinical studies on platinum-based antitumor agents will be presented. The chair will present new mechanistic results and developments in imaging and tracking of the intracellular fate of platinum drugs. In addition, the session chair will introduce the topic of new clinical trials, a theme to be further expanded on by invited speakers. Two industrial speakers will provide perspective on the latest clinical results of new agents and/or formulations in clinical trials as well as briefly give background on the processes of drug development including intellectual property, financing and regulatory (FDA approval) issues. Two academic speakers presentations will include description of (i) the chemistry, biology and clinical potential of a new class of drugs structurally distinct from that of the Cisplatin and (ii) the mechanistic and clinical implications of platinum drug cellular accumulation in Cisplatin-sensitive and resistant human tumor cells. |
| 9:00 am - 9:10 am | Discussion Leader: Nicholas P. Farrell (Virginia Commonwealth University)
"Introduction" |
| 9:10 am - 9:40 am | Stephen B. Howell (Moores UCSD Cancer Center)
"Copper transporters regulate the cellular pharmacology of the platinum drugs" |
| 9:40 am - 9:50 am | Discussion |
| 9:50 am - 10:20 am | Ulrich Bierbach (Wake Forrest University, NC)
"Non-crosslinking platinum-acridine agents: a new strategy for tackling chemoresistant cancers" |
| 10:20 am - 10:30 am | Discussion |
| 10:30 am - 11:00 am | Coffee Break |
| 11:00 am - 11:30 am | Michael Gottesman (National Cancer Institute, NIH)
"Novel cellular mechanisms of resistance to platinum chemotherapeutics" |
| 11:30 am - 11:40 am | Discussion |
| 11:40 am - 12:10 pm | Evelyne Vuaridel (Debiopharm)
"Oxaliplatin Formulations" |
| 12:10 pm - 12:30 pm | Discussion and General Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | New breaking topics I: Multidrug-Resistance, Alzheimers, and Epigenetic Mechanisms |
| Topics from areas in Multidrug resistance, Alzheimers and neurodegenerative illnesses, and Epigenic mechanisms of less common metals have been selected for presentation in this session. |
| Discussion Leader: Susan Doctrow (Boston University School of Medicine) |
| 7:30 pm - 8:00 pm | Charles E. McKenna (U Southern California)
"Translational potential on bisphosphonate nucleotide based drugs targeting beta polymerase" |
| 8:00 pm - 8:10 pm | Discussion |
| 8:10 pm - 8:40 pm | Katherine J. Franz (Duke University)
"Design of Triggerable Chelating Agents as Potential Therapeutics against Alzheimer’s Disease" |
| 8:40 pm - 8:50 pm | Discussion |
| 8:50 pm - 9:20 pm | Max Costa (Langone Medical Center, NYU)
"Epigenetic mechanisms of carcinogenesis probing the roles of Ni, As, and Cr" |
| 9:20 pm - 9:30 pm | Discussion |
| TUESDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Responsive Magnetic Resonance Imaging (MRI) Contrast Agents |
| This session introduced by Professor Angelique Louie covers the development of new metal ion based MRI contrast agents reporting on their environment through specific molecular recognition events. Such responsive agents would register changes in pH, temperature and even metabolite concentration and are presented by Eva Toth and by Janet Morrow. The development of MRI contrast agents that localize to a specific cell tissue type and may bind specifically to cell receptors or compounds on cell surfaces will be discussed by Silvio Aime and Yi Lu. |
| 9:00 am - 9:10 am | Discussion Leader: Angelique Louie (University of California, Davis)
"Introduction" |
| 9:10 am - 9:40 am | Eva Toth (Centre de Biophysique Moleculaire, CNRS, Orleans, France)
"Enzymatically activated PARACEST agents" |
| 9:40 am - 9:50 am | Discussion |
| 9:50 am - 10:20 am | Yi Lu (U Illinois, Urbana)
"Functional DNA in Biosensing, Bioimaging and Targeted Drug Delivery" |
| 10:20 am - 10:30 am | Discussion |
| 10:30 am - 11:00 am | Coffee Break |
| 11:00 am - 11:30 am | Silvio Aime (I.F.M., Italy)
"Metal containing nanosized system of MR imaging" |
| 11:30 am - 11:40 am | Discussion |
| 11:40 am - 12:10 pm | Janet Morrow (SUNY, Buffalo)
"Lanthanide complexes as responsive agents for optical and MR imaging" |
| 12:10 pm - 12:30 pm | Discussion and General Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Nuclear Medicine, Radioimmunotheraphy and Applications |
| A session including aspects of nuclear medicine, radioimmunotheraphy and applications of some well-known and novel clinically used agents, including Technetium, and Flourine-18 under development. Industrial participation and approaches in academia for translational research to document recent developments on its way and in the clinics. |
| Discussion Leader: Alan Packard (Children’s Hospital, Harvard Medical School) |
| 7:30 pm - 7:40 pm | Alan Packard (Children’s Hospital, Harvard Medical School)
"Introducing current advances and challenges in nuclear medicine and radioimmunotheraphy" |
| 7:40 pm - 8:10 pm | John F. Valliant (McMaster U /Centre for Probe Development and Commercialization, Ontario)
"Development and Evaluation of New Approaches for the Preparation of Organometallic Molecular Imaging and Therapy Agents" |
| 8:10 pm - 8:20 pm | Discussion |
| 8:20 pm - 8:50 pm | Simon Robinson (Lantheus)
"Discovery and development of a 18F pyridazinone analog, BMS747158, for myocardial perfusion PET imaging" |
| 8:50 pm - 8:55 pm | Discussion |
| 8:55 pm - 9:25 pm | Martin Breichbiel (NIH)
"Therapy with α-Emitters or Moby Dick" |
| 9:25 pm - 9:30 pm | Discussion |
| WEDNESDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | New Investigator, Student, Postdoctoral and Industrial Session |
| Presentations were selected from abstracts submitted by attendees to the 2010 Gordon Conference by the chairs and presiders. This session will allow us to showcase the young and researchers that have not previously presented at a GRC. Potential presenters indicate at the time of submission of their application to the GRC for acceptance to the Gordon Conference whether they are interested in contributing to this session. There will be three categories for these presentations, a session for students and postdoctoral fellows, a session for new investigators (defined as having attended less than 5 Gordon Conferences in the past) and Industrial Contributors. To be eligible to be considered for this conference the potential presenter must either be a student, a post doctoral fellow, a young investigator or having attended less than five Gordon Conferences in the past. |
| Discussion Leaders: Trevor Hambley (University of Sydney), A. Dean Sherry (University of Texas, Dallas) and Brian Day (Aeolus Pharmaceuticals, Inc) |
| 9:00 am - 10:45 am | Student and Postdoctoral Session |
| Discussion Leader: Trevor Hambley (University of Sydney) |
| 9:00 am - 9:10 am | Nora J.C. Graf (MIT)
"Pt(IV) encapsulated PLGA-PEG nanoparticles for targeting integrins in tumors" |
| 9:10 am - 9:15 am | Discussion |
| 9:15 am - 9:25 am | Jody M. Jourden (U. California, San Diego)
"Hydrogen Peroxide Activated Matrix Metalloproteinase Inhibitors" |
| 9:25 am - 9:30 am | Discussion |
| 9:30 am - 9:40 am | Peter W. Winter (Colorado State)
"Compartmentalization of insulin receptor by insulin and the insulin-like compound BMOV in live RBL-2H3 cells" |
| 9:40 am - 9:45 am | Discussion |
| 9:45 am - 9:55 am | Natsuho Yamamoto (U. Sydney, Australia)
"Visualising the Uptake of Fluorescently Tagged Cobalt Chaperone Bioconjugates in Solid Tumour Models" |
| 9:55 am - 10:00 am | Discussion |
| 10:00 am - 10:30 am | Coffee Break |
| 10:30 am - 10:40 am | Robert Radford (U. Cal. San Diego)
"Controlling Coordination Chemistry on Protein Surfaces" |
| 10:40 am - 10:45 am | Discussion |
| 10:45 am - 12:00 pm | Young or New Investigators to GRCs |
| Discussion Leader: A. Dean Sherry (University of Texas, Dallas) |
| 10:45 am - 10:55 am | Jennifer Dubois (Notre Dame)
"Iron Trafficking as an Antimicrobial Target -- a Strategy" |
| 10:55 am - 11:00 am | Discussion |
| 11:00 am - 11:10 am | Mi Hee Lim (University of Michigan)
"Development of Bifunctional Small Molecules Targeted To Metal-Aβ Species in Alzheimer's Disease" |
| 11:10 am - 11:15 am | Discussion |
| 11:15 am - 11:25 am | Suzanne Lapi (Washington University)
"Development of Zr-89, a longer lived PET radionuclide for molecular imaging" |
| 11:25 am - 11:30 am | Discussion |
| 11:30 am - 11:40 am | Jennifer C. Lee (NIH)
"Insights into Copper Coordination and Copper-dioxygen Reactivity of alpha-Synuclein" |
| 11:40 am - 11:45 am | Discussion |
| 11:45 am - 11:55 am | Maolin Guo (U. Massachusetts, Dartmouth)
"Novel profluorescent sensors for subcellular iron, copper and oxidative stress imaging in live neuronal cells" |
| 11:55 am - 12:00 pm | Discussion |
| 12:00 pm - 12:30 pm | Industrial Contributors |
| Discussion Leader: Brian Day (Aeolus Pharmaceuticals, Inc) |
| 12:00 pm - 12:10 pm | John L. McManus (Aeolus Pharmaceuticals, Inc.)
"AEOL 10150 - An SOD Mimetic with Potent Radioprotective Properties" |
| 12:10 pm - 12:15 pm | Discussion |
| 12:15 pm - 12:25 pm | Marc Robillard (Philips, NL)
"In Vivo Chemistry for Pretargeted Tumor Imaging in Live Mice" |
| 12:25 pm - 12:30 pm | Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session |
| 6:00 pm | Dinner |
| 7:00 pm - 7:30 pm | Business Meeting |
| (Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair) |
| 7:30 pm - 9:30 pm | Advances in The Design of Non-Pt Anticancer Agents |
| Clinical and pre-clinical studies on non-platinum-based antitumor agents will be presented as a follow up to the earlier session on Pt-agents. The chair will begin with an overview and new results and developments pointing to new promising drugs in the pipeline. Each of the speakers will cover different areas of non-platinum agents including, gold, and Ru. The targets, mechanism of action, pre-clinical and clinical implications will be described. |
| 7:30 pm - 7:40 pm | Discussion Leader: Peter Sadler (University of Warwick, England)
"Introduction" |
| 7:40 pm - 8:10 pm | Sue Berners-Price (Griffith University, Brisbane Australia)
"Gold-based, mitochondria-targeted anticancer compounds" |
| 8:10 pm - 8:15 pm | Discussion |
| 8:15 pm - 8:45 pm | Michael J. Hannon (University of Birmingham, England)
"Metal helicates and medicinal possibilities" |
| 8:45 pm - 8:50 pm | Discussion |
| 8:50 pm - 9:20 pm | Chi-Ming Che (University of Hong Kong)
"Anti-cancer gold complexes" |
| 9:20 pm - 9:30 pm | Discussion and General Discussion |
| THURSDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | New breaking topics II |
| Recent breakthroughs selected from areas in antimalarial drugs, Cu- and Fe-homeostasis from bacteria to patients and dermatology |
| Discussion Leader: Gail R. Willsky (The State University of New York, at Buffalo) |
| 9:00 am - 9:30 am | Bernard Meunier (Palumed)
"Heme as a key target for peroxide-containing antimalarial drugs" |
| 9:30 am - 9:45 am | Discussion |
| 9:45 am - 10:15 am | José Argüello (NSF/ Worcester Polytechnic Institute)
"Mechanisms of Copper homeostasis in eukaryotes and bacteria" |
| 10:15 am - 10:30 am | Discussion |
| 10:30 am - 11:00 am | Coffee Break |
| 11:00 am - 11:30 am | Peggy Carver (University of Michigan)
"Correlating plasma concentrations of iron and trace metal ions with Infection in patients undergoing long-term home total parenteral nutrition" |
| 11:30 am - 11:45 am | Discussion |
| 11:45 am - 12:15 pm | Lisa DeLouise (Dept. Dermatology, Rochester)
"Synthesis and characterization of quantum dots for application in studies of skin barrier function" |
| 12:15 pm - 12:30 pm | Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Targeting, Detection and Combatting Disease |
| Drug efficacy is improved significantly upon targeting, but with the complexities associated with metabolism remain a goal that researchers have been combating for significant time. In this section some of the recent successes will be presented. First, new approaches to electronically detecting proteins will be presented. Second, the in vivo imaging and therapeutic efficacy of a tumor-targeted corrole directed at the human epidermal growth factor receptor will be described. |
| 7:30 pm - 7:40 pm | Discussion Leader: Harry Gray (Caltech)
|
| 7:40 pm - 7:50 pm | TBA (Poster presenter selected from participant posters on-site) |
| 7:50 pm - 8:00 pm | Discussion |
| 8:00 pm - 8:35 pm | Thomas Meade (Northwestern)
"Electronically detecting proteins" |
| 8:35 pm - 8:45 pm | Discussion |
| 8:45 pm - 9:00 pm | Celine J. Marmion (Royal College of Surgeons in Ireland)
"Combating Cancer with Precious Metals: New Platinum Drug Candidates with Dual DNA Binding and Enzyme Inhibitory Activity" |
| 9:00 pm - 9:10 pm | Discussion |
| 9:10 pm - 9:20 pm | Nicola J. Farrer (University of Warwick, UK)
"Photoactivatable platinum anticancer complexes" |
| 9:20 pm - 9:30 pm | Discussion |
| FRIDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am | Depart |
